BioCentury
ARTICLE | Clinical News

ALT-801: Preliminary Phase I/II data

January 7, 2008 8:00 AM UTC

Preliminary data from an open-label, dose-escalation, U.S. Phase I/IIa trial (CA-ALT-801-01-06) showed no dose-limiting toxicities in the first cohort of patients receiving 0.015 mg/kg of IV ALT-801. ...